ART has improved the life expectancy (LE) of those with HIV. However, there is less information on LE changes in certain key populations living with HIV in the US, including Black men who have sex with men (MSM), Black women, Hispanics, people with a history of injecting drugs (PWID), and individuals co-infected with hepatitis C (HCV) in the more recent treatment era.
Using data from NA-ACCORD, we estimated LE after ART initiation in three time-periods (2005-07, 2008-11, 2012-15). Cohorts in the NA-ACCORD have previously demonstrated good ascertainment of deaths using active and passive methods. Standard abridged life table methodology was used to estimate LE for Black MSM (vs. white MSM), Black women (vs. white women), Hispanic (vs. non-Hispanic) adults, PWID (vs. those who do not) and HCV+ (vs. HCV-) adults with HIV.
Among 55,858 ART initiators who contributed 248,931 person-years and 3,123 deaths between 2005 to 2015, the LE increased in both men and women (Figure). LE increased in Black MSM over time, but was consistently lower than non-Black MSM in all time periods. Black women had a similar LE compared to white women in 2005-07, but had a greater LE in 2012-15. Hispanic adults had a greater LE compared to non-Hispanic adults in all time periods. Although PWID had little increase in LE, non-PWID saw an increase in LE from 2008-11 to 2012-15. Similarly, adults with HCV saw little increase in LE and did not exceed 50 years in any time period; however those without HCV had consistent increases in LE across time.
Although LE has improved since 2005 for most of these underserved populations, disparities persist. Factors that may be influencing the higher LE in Black compared to white women may be related to forces that are decreasing survival in whites in the US. The increased LE in Hispanics vs. non-Hispanics is reflective of what has been shown in the general US population. Adults with HIV and HCV saw very little (<2 years) increase in LE; further analysis reducing the influence of PWID are underway. Our LE results may be overestimated if NA-ACCORD cohorts under-represent those who are less likely to remain in care after ART initiation; estimates from 2012-15 are projections that are influenced by data truncated prior to 31 Dec 2015. The impact of the ‘treat all’ era and HCV direct acting agents may further increase LE, but may not narrow disparities in key populations if maintaining HIV RNA suppression is playing a significant role in these disparities.